Information  X 
Enter a valid email address

Medgenics Inc (MEDG)

  Print   

Wednesday 04 December, 2013

Medgenics Inc

Directors Dealings

RNS Number : 7033U
Medgenics Inc
04 December 2013
 



 

 

Press Release

04 December 2013

 

 

Directors Dealings

 

Medgenics, Inc. (AIM: MEDU, MEDG and NYSE MKT: MDGN), the developer of BiopumpTM, a novel technology for the sustained production and delivery of therapeutic proteins in patients using their own tissue, announces that on 2 December 2013 and 3 December 2013, the Company was informed by Dr. Eugene Bauer, a Director of the Company, that he sold a total of 20,000 shares of common stock on the open market on those days at an average price of $6.30 per share.

 

Following this sale Dr. Bauer owns 195,874 shares of common stock representing approximately 1.1 per cent of the issued share capital. Dr. Bauer also has the right to purchase up to 78,571 shares of common stock pursuant to warrants and options previously granted (in aggregate Dr. Bauer's shares of common stock, warrants, and options represent 274,445 shares of common stock which represent approximately 1.5 per cent of the issued share capital). 

 

This announcement is being made pursuant to the London Stock Exchange's AIM Rules for Companies admitted to trading on the AIM market.

 

 

About Medgenics

 

Medgenics is developing and commercializing Biopump™, a proprietary tissue-based platform technology for the sustained production and delivery of therapeutic proteins using the patient's own tissue for the treatment of a range of chronic diseases including anemia, hepatitis, among others.  For more information, please visit www.medgenics.com

 

 

 

Contacts:

 

Medgenics, Inc.

John Leaman, CFO

[email protected]

 

LHA

Anne Marie Fields

212-838-3777

[email protected]

@LHA_IR_PR

 


Abchurch Communications

Joanne Shears / Jamie Hooper / Harriet Rae

[email protected]

 

+44 207 398 7718

 

Oriel Securities (NOMAD & Broker)

Jonathan Senior / Giles Balleny

 

+44 207 710 7617 

 

 

 

-Ends-


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSUSAOROVAURAA

a d v e r t i s e m e n t